A detailed history of Jpmorgan Chase & CO transactions in Surmodics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 42,470 shares of SRDX stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,470
Previous 14,510 192.69%
Holding current value
$1.62 Million
Previous $610,000 169.84%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$38.47 - $42.24 $1.08 Million - $1.18 Million
27,960 Added 192.69%
42,470 $1.65 Million
Q2 2024

Aug 12, 2024

SELL
$25.39 - $42.1 $305,010 - $505,747
-12,013 Reduced 45.29%
14,510 $610,000
Q1 2024

May 10, 2024

BUY
$27.44 - $35.56 $334,850 - $433,938
12,203 Added 85.22%
26,523 $778,000
Q4 2023

Feb 12, 2024

BUY
$28.47 - $38.49 $74,619 - $100,882
2,621 Added 22.4%
14,320 $520,000
Q3 2023

Nov 14, 2023

SELL
$28.28 - $38.36 $35,745 - $48,487
-1,264 Reduced 9.75%
11,699 $375,000
Q2 2023

Aug 11, 2023

SELL
$17.67 - $31.31 $29,508 - $52,287
-1,670 Reduced 11.41%
12,963 $405,000
Q1 2023

May 18, 2023

BUY
$17.13 - $38.52 $178,871 - $402,225
10,442 Added 249.15%
14,633 $333,000
Q1 2023

May 11, 2023

SELL
$17.13 - $38.52 $153,005 - $344,060
-8,932 Reduced 68.06%
4,191 $95,000
Q4 2022

Feb 13, 2023

BUY
$29.44 - $37.31 $28,085 - $35,593
954 Added 7.84%
13,123 $449,000
Q3 2022

Nov 14, 2022

BUY
$28.84 - $38.92 $21,082 - $28,450
731 Added 6.39%
12,169 $369,000
Q2 2022

Aug 11, 2022

BUY
$33.25 - $45.11 $41,196 - $55,891
1,239 Added 12.15%
11,438 $426,000
Q1 2022

May 11, 2022

SELL
$40.68 - $49.72 $70,213 - $85,816
-1,726 Reduced 14.47%
10,199 $462,000
Q4 2021

Feb 10, 2022

SELL
$43.21 - $57.6 $18,882 - $25,171
-437 Reduced 3.54%
11,925 $574,000
Q3 2021

Nov 12, 2021

BUY
$52.8 - $60.32 $652,713 - $745,675
12,362 New
12,362 $687,000

Others Institutions Holding SRDX

About SURMODICS INC


  • Ticker SRDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 14,005,000
  • Market Cap $533M
  • Description
  • Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device s...
More about SRDX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.